LEXINGTON, Massachusetts, November 16, 2016 /PRNewswire/ -- CUVITRU, now available in the U.S., expandsShire's immunoglobulin portfolioof treatment optionstomeet the unique needs of children and adults living withprimary immunodeficiency Shire plc (LSE: SHP, NASDAQ: SHPG) announces the launch of CUVITRU [Immune Globulin Subcutaneous (Human), 20% ution]¿, the first and only Subcutaneous 20% treatment option without proline available in the U.S. to treat adult and pediatric patients (two years of age and older) with primary immunodeficiency (PI). The U.S. Food and Drug Administration (FDA) approved CUVITRU in September 2016 as a subcutaneous immune globulin (IG) replacement therapy for PI, a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly, in some cases making it more difficult to fight off infections. , PI affects up to six million people worldwide. , People living with PI often face significant challenges relating to their disease and treatment. CUVITRU offers patients flexibility and control to manage their treatment in a way that best fits their needs and condition. In clinical trials, CUVITRU was infused weekly in under an hour in one to two sites for most patients. However, CUVITRU can be administered daily to biweekly and in up to four infusion sites, based on a patient's individual needs. CUVITRU is also the only 20% subcutaneous IG treatment option with the ability to infuse up to 60 mL (12 grams) per site and up to 60 mL per hour per site, as tolerated, allowing for fewer infusion sites and shorter infusion durations compared to other conventional subcutaneous IG treatments.